S&P 500 Closes At Record High Ahead Of Inflation Data: Fear & Greed Index Remains In 'Neutral' Zone
The CNN Money Fear and Greed index showed a slight decline in the overall market sentiment, while the index remained in the "Neutral" zone on Monday.U.S. stocks closed mixed on Monday, with the S&P 50
Eli Lilly's Mounjaro Outpaces Novo Nordisk's Ozempic In Weight Loss Effectiveness, Study Shows
Eli Lilly and Co. (NYSE:LLY) has come out on top in a weight loss drug competition in a recent study.
Study Finds Patients Lost More Weight on Mounjaro Than Ozempic
The US stock market is mixed, waiting for inflation indicators and testimony from Powell, the chairman of the Federal Reserve (on the 8th).
The US stock market is mixed. The Dow Inc ended trading at 39,344.79, down 31.08 points, while the Nasdaq ended trading at 18,403.74, up 50.98 points.
Dow Turns Lower; Myomo Shares Jump
U.S. stocks traded mixed midway through trading, with the Dow Jones index turning lower on Monday.The Dow traded down 0.19% to 39,301.00 while the NASDAQ rose 0.21% to 18,390.4. The S&P 500 also fell,
'Zepbound Sheds More Weight Than Wegovy, Study Finds' - Forbes
Eli Lilly's popular obesity injection Zepbound trounces Novo Nordisk's Wegovy when it comes to shedding weight, according to new research published Monday, intensifying competition between the two pha
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $5,900 Today
Boston Scientific (NYSE:BSX) has outperformed the market over the past 10 years by 8.59% on an annualized basis producing an average annual return of 19.49%. Currently, Boston Scientific has a market
$1000 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today
AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.09% on an annualized basis producing an average annual return of 12.01%. Currently, AbbVie has a market capitalization of $29
Eli Lilly's First Biotech Deal Of 2024, Buys Chronic Disease Player Morphic For $3.2B
Monday, Eli Lilly And Co (NYSE:LLY) agreed to acquire Morphic Holding Inc (NASDAQ:MORF) for $57 per share in cash, an aggregate of approximately $3.2 billion.Morphic is a biopharmaceutical company dev
Ideaya Stock Jumps After Positive Study Data From Cancer Study
Latest report on active-management mutual funds in USA: Only 15 out of 1218 funds suffered losses.
The winning strategy of these top-ranked actively managed public funds is to heavily invest in the 'Seven Giants of the US Stock Market' that have caught onto the AI trend.
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs, who shared this optimistic forecast in an exclusive interview with Benzinga.
Small, Mid-size Biotechs Could See M&A Action in H2 - PwC
(PODD) - Analyzing Insulet's Short Interest
Insulet's (NYSE:PODD) short percent of float has fallen 9.44% since its last report. The company recently reported that it has 2.71 million shares sold short, which is 5.18% of all regular shares that
Study Links GLP-1 Drugs, Metformin to Lower Risk of Certain Cancers
What's Going On With Eli Lilly Shares Friday?
Eli Lilly and Co. (NYSE:LLY) shares are experiencing increased activity Friday afternoon. Here's what you need to know.What's Happening: Morgan Stanley has maintained its Overweight rating on Eli Lill
GLP-1 Treatments Such As Wegvoy, Mounjaro Cut Obesity-Related Cancer Risks, Study Finds
In a study published in JAMA Network, patients with type 2 diabetes taking GLP-1 treatments have a reduced risk of developing ten types of obesity-related cancers compared to those on insulin and othe
$100 Invested In Intuitive Surgical 20 Years Ago Would Be Worth This Much Today
Intuitive Surgical (NASDAQ:ISRG) has outperformed the market over the past 20 years by 21.89% on an annualized basis producing an average annual return of 30.21%. Currently, Intuitive Surgical has a m
Smart Money Is Betting Big In LLY Options
High-rolling investors have positioned themselves bearish on Eli Lilly and Co (NYSE:LLY), and it's important for retail traders to take note.\This activity came to our attention today through Benzinga
Eli Lilly and Co Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/05/2024 14.02% Morgan Stanley $1023 → $1023 Maintains Overweight 07/03/2024 11.57% BMO Capital $1001 →